Targeting epigenetic regulatory mechanisms in cancer chemoprevention

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 2, 2005, Pages 315-328

  Fay, Judith R ^a   Crowell, James A ^b   Kopelovich, Levy ^b  

^a CCS Associates   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Chemoprevention; DNA methylation; Epigenetics; Histone modification

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; AZACITIDINE; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; DEPSIPEPTIDE; DNA METHYLTRANSFERASE; EPIGALLOCATECHIN GALLATE; GENOMIC DNA; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; METHYLTRANSFERASE INHIBITOR; MG 98; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PHENYLBUTAZONE; PIVALOYLOXYMETHYL BUTYRATE; PROCAINAMIDE; PROCAINE; RNA; SK 7041; TETRAPEPTIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; DNA METHYLATION; DNA REPAIR; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; EPIGENETICS; ESOPHAGUS CANCER; GENE ACTIVATION; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; GENETIC REGULATION; HUMAN; IC 50; LUNG CANCER; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRECANCER; PROSTATE CANCER; REVIEW; SIDE EFFECT; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS;

EID: 18144384816     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.2.315     Document Type: Review

References (132)

1. KELLOFF GJ: Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res. (2000) 78:199-334.
2. KOPELOVICH L, HENSON DE, GAZDAR AF et al.: Surrogate anatomic/functional sites for evaluating cancer risk: Extension of the field effect. Clin. Cancer Res. (1999) 5:3899-3905.
3. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100:57-70.
4. FEINBERG AP, TYCKO B: The history of cancer epigenetics. Nat. Rev. Cancer (2004) 4:143-153.
5. JONES PA, BAYLIN SB: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. (2002) 3:415-428.
6. JOHNSTONE RW: Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. (2002) 1:287-299.
7. MARKS PA, MILLER T, RICHON VM: Histone deacetylases. Curr. Opin. Pharmacol. (2003) 3:344-351.
8. HAKE SB, XIAO A, ALLIS CD: Linking the epigenetic 'language' of covalent histone modifications to cancer. Br. J. Cancer (2004) 90:761-769.
9. HERMAN JG, BAYLIN SB: Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. (2003) 349:2042-2054.
10. FEINBERG AP, VOGELSTEIN B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (1983) 301:89-92.
11. GAMA-SOSA MA, SLAGEL VA, TREWYN RW et al.: The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. (1983) 11:6883-6894.
12. GOELZ SE, VOGELSTEIN B, HAMILTON SR, FEINBERG AP: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science (1985) 228:187-190.
13. EHRLICH M: DNA methylation in cancer: Too much, but also too little. Oncogene (2002) 21:5400-5413.
14. COSTELLO JF, FRUHWALD MC, SMIRAGLIA DJ et al.: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. (2000) 25:132-138.
15. KOPELOVICH L, CROWELL JA, FAY JR: The epigenome as a target for cancer chemoprevention. J. Natl. Cancer Inst. (2003) 95:1747-1757.
16. NAKAGAWA H, NUOVO GJ, ZERVOS EE et al.: Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res. (2001) 61:6991-6995.
17. PALMISANO WA, DIVINE KK, SACCOMANNO G et al.: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. (2000) 60:5954-5958.
18. BROOKS JD, WEINSTEIN M, LIN X et al.: CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomarkers Prev. (1998) 7:531-536.
19. SUTER CM, MARTIN DI, WARD RL: Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet. (2004) 36:497-501.
20. EHRLICH M, JIANG G, FIALA E et al.: Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene (2002) 21:6694-6702.
21. BARIOL C, SUTER C, CHEONG K et al.: The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am. J. Pathol. (2003) 162:1361-1371.
22. VIGUSHIN DM, COOMBES RC: Targeted histone deacetylase inhibition for cancer therapy. Curr. Cancer Drug Targets (2004) 4:205-218.
23. STRAHL BD, ALLIS CD: The language of covalent histone modifications. Nature (2000) 403:41-45.
24. GRIGNANI F, DE MATTEIS S, NERVI C et al.: Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 391:815-818.
25. ZHU P, MARTIN E, MENGWASSER J, SCHLAG P, JANSSEN K-P, GOTTLICHER M: Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell (2004) 5:455-463.
26. VARAMBALLY S, DHANASEKARAN SM, ZHOU M et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 419:624-629.
27. KLEER CG, CAO Q, VARAMBALLY S et al.: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA (2003) 100:11606-11611.
28. NGUYEN CT, WEISENBERGER DJ, VELICESCU M et al.: Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res. (2002) 62:6456-6461.
29. NELSON WG, DE MARZO AM, DEWEESE TL et al.: Preneoplastic prostate lesions: An opportunity for prostate cancer prevention. Ann. N.Y. Acad. Sci. (2001) 952:135-144.
30. JERONIMO C, VARZIM G, HENRIQUE R et al.: I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. (2002) 11:445-450.
31. YAMANAKA M, WATANABE M, YAMADA Y et al.: Altered methylation of multiple genes in carcinogenesis of the prostate. Int. J. Cancer (2003) 106:382-387.
32. KANG GH, LEE S, LEE HJ, HWANG KS: Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J. Pathol. (2004) 202:233-240.
33. WOODSON K, GILLESPIE J, HANSON J et al.: Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: A histopathologic study of whole mount prostate specimens. Prostate (2004) 60:25-31.
34. SONG JZ, STIRZAKER C, HARRISON J, MELKI JR, CLARK SJ: Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene (2002) 21:1048-1061.
35. GONZALGO ML, PAVLOVICH CP, LEE SM, NELSON WG: Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res. (2003) 9:2673-2677.
36. GOESSL C, MULLER M, HEICAPPELL R et al.: DNA-based detection of prostate cancer in urine after prostatic massage. Urology (2001) 58:335-338.
37. JERONIMO C, HENRIQUE R, HOQUE MO et al.: Quantitative RARβ2 hypermethylation: A promising prostate cancer marker. Clin. Cancer Res. (2004) 10:4010-4014.
38. HALKIDOU K, GAUGHAN L, COOK S, LEUNG HY, NEAL DE, ROBSON CN: Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate (2004) 59:177-189.
39. FU M, WANG C, ZHANG X, PESTELL RG: Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem. Pharmacol. (2004) 68:1199-1208.
40. HONG H, KAO C, JENG MH et al.: Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer (2004) 101:83-89.
41. KONDO Y, ISSA J-PJ: Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. (2004) 23:29-39.
42. AHUJA N, LI Q, MOHAN AL, BAYLIN SB, ISSA J-PJ: Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. (1998) 58:5489-5494.
43. CHAN AO, BROADDUS RR, HOULIHAN PS, ISSA J-PJ, HAMILTON SR, RASHID A: CpG island methylation in aberrant crypt foci of the colorectum. Am. J. Pathol (2002) 160:1823-1830.
44. INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res. (1998) 58:3942-3945.
45. HAWKINS NJ, WARD RL: Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J. Natl. Cancer Inst. (2001) 93:1307-1313.
46. JASS JR, YOUNG J, LEGGETT BA: Evolution of colorectal cancer: Change of pace and change of direction. J. Gastroenterol. Hepatol. (2002) 17:17-26.
47. SUZUKI H, WATKINS DN, JAIR K-W et al.: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. (2004) 36:417-422.
48. FEARNHEAD NS, BRITTON MP, BODMER WF: The ABC of APC. Hum. Mol. Genet. (2001) 10:721-733.
49. LAIRD PW, JACKSON-GRUSBY L, FAZELI A et al.: Suppression of intestinal neoplasia by DNA hypomethylation. Cell (1995) 81:197-205.
50. Min/+ Dnmt1-hypomorphic mice. Cancer Res. (2002) 62:1296-1299.
51. TRINH BN, LONG TI, NICKEL AE, SHIBATA D, LAIRD PW: DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol. Cell Biol. (2002) 22:2906-2917.
52. CUI H, CRUZ-CORREA M, GIARDIELLO FM et al.: Loss of IGF2 imprinting: A potential marker of colorectal cancer risk. Science (2003) 299:1753-1755.
53. WIDSCHWENDTER M, JONES PA: DNA methylation and breast carcinogenesis. Oncogene (2002) 21:5462-5482.
54. LEHMANN U, LANGER F, FEIST H, GLOCKNER S, HASEMEIER B, KREIPE H: Quantitative assessment of promoter hypermethylation during breast cancer development. Am. J. Pathol. (2002) 160:605-612.
55. HONORIO S, AGATHANGGELOU A, SCHUERMANN M et al.: Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene (2003) 22:147-150.
56. FACKLER MJ, MCVEIGH M, EVRON E et al.: DNA methylation of RASSF1A, HIN-1, RAR-β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int. J. Cancer (2003) 107:970-975.
57. PU RT, LAITALA LE, ALLI PM, FACKLER MJ, SUKUMAR S, CLARK DP: Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod. Pathol. (2003) 16:1095-1101.
58. KRASSENSTEIN R, SAUTER E, DULAIMI E et al.: Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin. Cancer Res. (2004) 10:28-32.
59. EVRON E, DOOLEY WC, UMBRICHT CB et al.: Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet (2001) 357:1335-1336.
60. LEHMANN U, CELIKKAYA G, HASEMEIER B, LANGER F, KREIPE H: Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res. (2002) 62:6634-6638.
61. FUQUA SAW, WILTSCHKE C, ZHANG QX et al.: A hypersensitive estrogen receptor-α mutation in premalignant breast lesions. Cancer Res. (2000) 60:4026-4029.
62. MCMANUS DT, OLARU A, MELTZER SJ: Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res. (2004) 64:1561-1569.
63. BIAN Y-S, OSTERHELD M-C, FONTOLLIET C, BOSMAN FT, BENHATTAR J: p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology (2002) 122:1113-1121.
64. KLUMP B, HSIEH C-J, HOLZMANN K, GREGOR M, PORSCHEN R: Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology (1998) 115:1381-1386.
65. MALEY CC, GALIPEAU PC, LI X, SANCHEZ CA, PAULSON TG, REID BJ: Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res. (2004) 64:3414-3427.
66. NIE Y, LIAO J, ZHAO X, SONG Y, YANG G-Y, WANG L-D, YANG CS: Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis (2002) 23:1713-1720.
67. EADS CA, LORD RV, WICKRAMASINGHE K et al.: Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. (2001) 61:3410-3418.
68. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA (1998) 95:11891-11896.
69. INK4a gene promoter region in preinvasive bronchial lesions: A prospective study in high-risk patients without invasive cancer. Int. J. Cancer (2002) 100:189-193.
70. BELINSKY SA, PALMISANO WA, GILLILAND FD et al.: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. (2002) 62:2370-2377.
71. SORIA J-C, RODRIGUEZ M, LIU DD, LEE JJ, HONG WK, MAO L: Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res. (2002) 62:351-355.
72. INK4a promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J. Clin. Oncol. (2000) 18:3221-3229.
73. GUO M, HOUSE MG, HOOKER C et al.: Promoter hypermethylation of resected bronchial margins: A field defect of changes? Clin. Cancer Res. (2004) 10:5131-5136.
74. ZOCHBAUER-MULLER S, LAM S, TOYOOKA S et al.: Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int. J. Cancer (2003) 107:612-616.
75. PULLING LC,VUILLEMENOT BR, HUTT JA, DEVEREUX TR, BELINSKY SA: Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens. Cancer Res. (2004) 64:3844-3848.
76. VUILLEMENOT BR, PULLING LC, PALMISANO WA, HUTT JA, BELINSKY SA: Carcinogen exposure differentially modulates RAR-β promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis. Carcinogenesis (2004) 25:623-629.
77. BELINSKY SA, KLINGE DM, STIDLEY CA et al.: Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. (2003) 63:7089-7093.
78. LAWRENCE LW: Refractory anemia and the myelodysplastic syndromes. Clin. Lab. Sci. (2004) 17: 178-186.
79. INK4B gene in myelodysplastic syndromes. Blood (1997) 90:1403-1409.
80. BRUECKNER B, LYKO F: DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol. Sci. (2004) 25:551-554.
81. DASKALAKIS M, NGUYEN TT, NGUYEN C et al.: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood (2002) 100:2957-2964.
82. ISSA JP, GARCIA-MANERO G, GILES FJ et al.: Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2004) 103:1635-1640.
83. LEE S, LEE HJ, KIM J-H, LEE H-S, JANG JJ, KANG GH: Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am. J. Pathol. (2003) 163:1371-1378.
84. CHILES MC, AI L, ZUO C, FAN C-Y, SMOLLER BR: E-cadherin promoter hypermethylation in preneoplastic and neoplastic skin lesions. Mod. Pathol. (2003) 16:1014-1018.
85. CHRISTMAN JK: 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene (2002) 21:5483-5495.
86. YOO CB, CHENG JC, JONES PA: Zebularine: a new drug for epigenetic therapy. Biochem Soc. Trans. (2004) 32(Pt 6):910-912.
87. GIUS D, CUI H, BRADBURY CM et al.: Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell (2004) 6:361-371.
88. JÜTTERMANN R, LI E, JAENISCH R: Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl. Acad. Sci. USA (1994) 91:11797-11801.
89. SZYF M: Targeting DNA methylation in cancer. Ageing Res. Rev. (2003) 2:299-328.
90. CHENG JC, MATSEN CB, GONZALES FA et al.: Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst. (2003) 95:399-409.
91. CHENG JC, WEISENBERGER DJ, GONZALES FA et al.: Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell. Biol. (2004) 24:1270-1278.
92. CHENG JC, YOO CB, WEISENBERGER DJ et al.: Preferential response of cancer cells to zebularine. Cancer Cell (2004) 6:151-158.
93. LIN X, ASGARI K, PUTZI MJ et al.: Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. (2001) 61:8611-8616.
94. VILLAR-GAREA A, FRAGA MF, ESPADA J, ESTELLER M: Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. (2003) 63:4984-4989.
95. DENG C, LU Q, ZHANG Z, RAO T, ATTWOOD J, YUNG R, RICHARDSON B: Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum. (2003) 48:746-756.
96. PINA IC, GAUTSCHI JT, WANG GY et al.: Psammaplins from the sponge Pseudoceratina purpurea: Inhibition of both histone deacetylase and DNA methyltransferase. J. Org. Chem (2003) 68:3866-3873.
97. FANG MZ, WANG Y, AI N et al.: Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. (2003) 63:7563-7570.
98. VILLAR-GAREA A, ESTELLER M: DNA demethylating agents and chromatin-remodelling drugs: which, how and why? Curr. Drug Metab. (2003) 4:11-31.
99. DAVIS AJ, GELMON KA, SIU LL et al.: Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest. New Drugs. (2003) 21:85-97.
100. ROBERT M-F, MORIN S, BEAULIEU N et al.: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat. Genet. (2003) 33:61-65.
101. KIM MS, KWON HJ, LEE YM et al.: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med (2001) 7:437-443.
102. JOHNSTONE RW, LICHT JD: Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell (2003) 4:13-18.
103. ROSATO RR, GRANT S: Histone deacetylase inhibitors in clinical development. Expert Opin. Investig. Drugs. (2004) 13:21-38.
104. DETICH N, BOVENZI V, SZYF M: Valproate induces replication-independent active DNA demethylation. J. Biol Chem. (2003) 278:27586-27592.
105. 2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J. Med. Chem. (2004) 47:467-474.
106. PARK JH, JUNG Y, KIM TY et al.: Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. (2004) 10:5271-5281.
107. ZELENT A, WAXMAN S, CARDUCCI M, WRIGHT J, ZWEIBEL J, GORE SD: State of the translational science: summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer; January 2003. Clin. Cancer Res. (2004) 10:4622-4629.
108. DAVIS CD, UTHUS EO: Dietary selenite and azadeoxycytidine treatments affect dimethylhydrazine-induced aberrant crypt formation in rat colon and DNA methylation in HT-29 cells. J. Nutr. (2002) 132:292-297.
109. LANTRY LE, ZHANG Z, CRIST KA et al.: 5-Aza-2′-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. Carcinogenesis (1999) 20:343-346.
110. FIALA ES, STARETZ ME, PANDYA GA, EL-BAYOUMY K, HAMILTON SR: Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for DNA cytosine methyltransferase and DNA cytosine methylation. Carcinogenesis (1998) 19:597-604.
111. COHEN LA, AMIN S, MARKS PA, RIFKIND RA, DESAI D, RICHON VM: Chemoprevention of carcinogen-induced mammary tumorigenesis by hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anti-Cancer Res. (1999) 19:4999-5005.
112. COHEN LA, MARKS PA, RIFKIND RA et al.: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumours. Anti-Cancer Res. (2002) 22:1497-1504.
113. DESAI, D, DAS A, COHEN L, EL-BAYOUMY K, AMIN S: Chemopreventive efficacy of suberoylanilide hydroxamic acid (SAHA) against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumorigenesis in female A/J mice. Anti-Cancer Res. (2003) 23:499-503.
114. WARGOVICH MJ, JIMENEZ A, MCKEE K et al.: Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis (2000) 21:1149-1155.
115. WARGOVICH MJ, CHEN C.D, JIMENEZ A et al.: Aberrant crypts as a biomarker for colon cancer: Evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol. Biomarkers Prev. (1996) 5:355-360.
116. +/+ mice. Anti-Cancer Res. (2004) 24:785-790.
117. MYZAK MC, KARPLUS PA, CHUNG FL, DASHWOOD RH: A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase. Cancer Res. (2004) 64:5767-5774.
118. CAMERON EE, BACHMAN KE, MYOHANEN S, HERMAN JG, BAYLIN SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. (1999) 21:103-107.
119. ZHU W-G, OTTERSON GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anti-Cancer Agents (2003) 3:187-199.
120. WIDSCHWENDTER M, JONES PA: The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer: Commentary Re: J Kwong et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. (2002) 8:131-137 and H-Z Zou et al. Clin. Cancer Res. (2002) 8:17-21.
121. FERRARA FF, FAZI F, BIANCHINI A et al.: Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. (2001) 61:2-7.
122. COTE S, MOMPARLER RL: Activation of the retinoic acid receptor beta gene by 5-aza-2′-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs (1997) 8:56-61.
123. WIDSCHWENDTER M, BERGER J, HERMANN M et al.: Methylation and silencing of the retinoic acid receptor-β2 gene in beast cancer. J. Natl. Cancer Inst. (2000) 92:826-832.
124. GARBER K. Synthetic lethality: killing cancer with cancer. J. Natl. Cancer Inst. (2000) 94:1666-1668.
125. KOZAR K, KAMINSKI R, SWITAJ T et al.: Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2′-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin. Cancer Res. (2003) 9:3124-3133.
126. LIANG G, GONZALES FA, JONES PA, ORNTOFT TF, THYKJAER T: Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res. (2002) 62:961-966.
127. PAKNESHAN P, SZYF M, FARIAS-EISNER R, RABBANI SA: Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J. Biol. Chem. (2004) 279:31735-31744.
128. GAUDET F, HODGSON JG, EDEN A et al.: Induction of tumors in mice by genomic hypomethylation. Science (2003) 300:489-492.
129. EDEN A, GAUDET F, WAGHMARE A, JAENISCH R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science (2003) 300:455.
130. RHEE I, BACHMAN KE, PARK BH et al.: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002). 416:552-556.
131. TING AH, JAIR K-W, SUZUKI H, YEN R-WC, BAYLIN SB, SCHUEBEL KE: CpG island hypermethylation is maintained in human colorectal cancer cells after RNAi-mediated depletion of DNMT1. Nat. Genet. (2004) 36:582-584.
132. LAIRD PW: The power and the promise of DNA methylation markers. Nat. Rev. Cancer (2003) 3:253-266.